IA
TCRR

IndexIQ Advisors’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

IndexIQ Advisors’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,126
Closed -$89K – 1564
2021
Q4 		$89K Sell
19,126
-1,236
-6% -$7.73K ﹤0.01% 1088
2021
Q3 		$173K Buy
20,362
+2,039
+11% +$28.8K 0.01% 1052
2021
Q2 		$301K Sell
18,323
-900
-5% -$18.2K 0.01% 979
2021
Q1 		$424K Sell
19,223
-7,837
-29% -$214K 0.02% 442
2020
Q4 		$837K Buy
27,060
+2,794
+12% +$70.6K 0.03% 262
2020
Q3 		$493K Buy
24,266
+1,316
+6% +$23.1K 0.02% 279
2020
Q2 		$353K Sell
22,950
-5,481
-19% -$63.2K 0.02% 295
2020
Q1 		$220K Buy
+28,431
New +$348K 0.01% 279

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

IndexIQ Advisors's TCRR Position: Q1 2022 in Review

IndexIQ Advisors sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 19,126 shares — an estimated $89K sold.

IndexIQ Advisors first reported a position in TCRR in Q1 2020 and held it in 8 quarters. The position peaked at $837K in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • IndexIQ Advisors reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 19,126 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $89K.
  • IndexIQ Advisors first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 8 quarters.
  • IndexIQ Advisors's TCR2 Therapeutics Inc. Common Stock position peaked at $837K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.